Quantcast

Latest Halozyme Therapeutics Inc. Stories

2014-05-05 16:28:04

SAN DIEGO, May 5, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2014 on Monday, May 12, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2014. The call will be webcast live through the "Investors" section of Halozyme's corporate website and a...

2014-04-09 08:28:52

SAN DIEGO, April 9, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. According to the FDA, this action was being taken in view of the company's recent decision to temporarily halt enrollment...

2014-04-08 08:32:31

Additional preclinical data highlights the pharmacologic properties of PEGPH20 SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the American Association for Cancer Research (AACR) annual meeting being held in San Diego. The first presentation includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of...

2014-04-04 08:25:23

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. The DMC is assessing clinical data that indicates a possible difference in the thromboembolic event rate between the...

2014-04-02 08:33:07

SAN DIEGO, April 2, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Sunil Joshi as Vice President and Global Product Team Lead (GPTL), for PEGPH20 and Oncology. With over 20 years of experience in the biopharmaceutical industry, Mr. Joshi brings strong expertise in oncology drug development and commercialization. Mr. Joshi most recently served as Head of New Product Strategy and Commercial Assessment at Onyx Pharmaceuticals where he...

2014-03-31 08:29:38

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex(® )recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin...

2014-03-28 08:26:35

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(®)( )(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in...

2014-03-25 08:29:27

SAN DIEGO, March 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced top-line data from a proof of concept Phase 1/2 clinical trial evaluating the use of HTI-501 in the treatment of cellulite. The primary endpoint of the clinical trial was met, showing a statistically significant improvement in the appearance of cellulite in the areas of the patients' skin treated with HTI-501 as determined by physician assessment 28 days after treatment compared to...

2014-03-05 08:29:00

SAN DIEGO, March 5, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2014 Global Healthcare Conference in Miami, FL on March 11, 2014 at 2:00 p.m. ET/11:00 a.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview. http://photos.prnewswire.com/prnvar/20100302/LA63139LOGO The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a...

2014-02-27 16:28:39

SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2013. Financial highlights for the fourth quarter include revenues of $12.5 million and a net loss of $22.0 million, or $0.19 per share. This compares to revenues of $21.8 million and a net loss of $4.4 million, or $0.04 per share, for the fourth quarter of 2012. Financial highlights for the full year 2013 include...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related